Using low-molecular-weight heparin (LMWH), outcomes such as live birth rate and the occurrence of pregnancy complications are some of the variables reported in some studies, with varying degrees of success. The present study aimed to compare the role of LMWH in unexplained recurrent pregnancy loss.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
175
A daily dose of 40 mg of low-molecular-weight heparin (LMWH) subcutaneously was given to the patients.
DG Khan Hospital
Dera Ghazi Khan, Punjab Province, Pakistan
Efficacy of Low-Molecular-Weight Heparin
Efficacy was labeled as yes in terms of live births after the age of viability, i.e., 24 weeks of gestation.
Time frame: 32 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.